- Home
- NBBK vs TRVI Comparison
NBBK vs TRVI Comparison
Compare NBBK & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- TRVI
- Stock Information
- Founded
- NBBK 1892
- TRVI 2011
- Country
- NBBK United States
- TRVI United States
- Employees
- NBBK N/A
- TRVI N/A
- Industry
- NBBK
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- TRVI Health Care
- Exchange
- NBBK Nasdaq
- TRVI Nasdaq
- Market Cap
- NBBK 661.3M
- TRVI 629.8M
- IPO Year
- NBBK N/A
- TRVI 2019
- Fundamental
- Price
- NBBK $16.22
- TRVI $6.09
- Analyst Decision
- NBBK Buy
- TRVI Strong Buy
- Analyst Count
- NBBK 1
- TRVI 8
- Target Price
- NBBK $22.00
- TRVI $19.31
- AVG Volume (30 Days)
- NBBK 295.7K
- TRVI 2.4M
- Earning Date
- NBBK 07-23-2025
- TRVI 08-07-2025
- Dividend Yield
- NBBK N/A
- TRVI N/A
- EPS Growth
- NBBK 421.39
- TRVI N/A
- EPS
- NBBK 1.18
- TRVI N/A
- Revenue
- NBBK $169,131,000.00
- TRVI N/A
- Revenue This Year
- NBBK N/A
- TRVI N/A
- Revenue Next Year
- NBBK N/A
- TRVI N/A
- P/E Ratio
- NBBK $13.79
- TRVI N/A
- Revenue Growth
- NBBK 27.71
- TRVI N/A
- 52 Week Low
- NBBK $14.20
- TRVI $2.36
- 52 Week High
- NBBK $21.05
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- NBBK 39.05
- TRVI 44.98
- Support Level
- NBBK $15.44
- TRVI $5.38
- Resistance Level
- NBBK $17.05
- TRVI $6.58
- Average True Range (ATR)
- NBBK 0.39
- TRVI 0.53
- MACD
- NBBK -0.03
- TRVI -0.04
- Stochastic Oscillator
- NBBK 45.09
- TRVI 33.81
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.